1224 related articles for article (PubMed ID: 27048650)
21. Metabolic control of YAP and TAZ by the mevalonate pathway.
Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
[TBL] [Abstract][Full Text] [Related]
22. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
24. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
[TBL] [Abstract][Full Text] [Related]
25. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
[TBL] [Abstract][Full Text] [Related]
26. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.
Liu F; Lagares D; Choi KM; Stopfer L; Marinković A; Vrbanac V; Probst CK; Hiemer SE; Sisson TH; Horowitz JC; Rosas IO; Fredenburgh LE; Feghali-Bostwick C; Varelas X; Tager AM; Tschumperlin DJ
Am J Physiol Lung Cell Mol Physiol; 2015 Feb; 308(4):L344-57. PubMed ID: 25502501
[TBL] [Abstract][Full Text] [Related]
27. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway.
Chan P; Han X; Zheng B; DeRan M; Yu J; Jarugumilli GK; Deng H; Pan D; Luo X; Wu X
Nat Chem Biol; 2016 Apr; 12(4):282-9. PubMed ID: 26900866
[TBL] [Abstract][Full Text] [Related]
28. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
[TBL] [Abstract][Full Text] [Related]
29. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.
Hansen CG; Ng YL; Lam WL; Plouffe SW; Guan KL
Cell Res; 2015 Dec; 25(12):1299-313. PubMed ID: 26611634
[TBL] [Abstract][Full Text] [Related]
30. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
31. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype.
Anorga S; Overstreet JM; Falke LL; Tang J; Goldschmeding RG; Higgins PJ; Samarakoon R
FASEB J; 2018 May; 32(5):2644-2657. PubMed ID: 29298862
[TBL] [Abstract][Full Text] [Related]
32. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
[TBL] [Abstract][Full Text] [Related]
33. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
[TBL] [Abstract][Full Text] [Related]
34. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
35. Role of LPA and the Hippo pathway on apoptosis in salivary gland epithelial cells.
Hwang SM; Jin M; Shin YH; Ki Choi S; Namkoong E; Kim M; Park MY; Park K
Exp Mol Med; 2014 Dec; 46(12):e125. PubMed ID: 25502757
[TBL] [Abstract][Full Text] [Related]
36. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP
J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868
[TBL] [Abstract][Full Text] [Related]
37. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
Miesfeld JB; Link BA
Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
[TBL] [Abstract][Full Text] [Related]
38. The Hippo Pathway in Prostate Cancer.
Salem O; Hansen CG
Cells; 2019 Apr; 8(4):. PubMed ID: 31018586
[TBL] [Abstract][Full Text] [Related]
39. YAP and TAZ are distinct effectors of corneal myofibroblast transformation.
Muppala S; Raghunathan VK; Jalilian I; Thomasy S; Murphy CJ
Exp Eye Res; 2019 Mar; 180():102-109. PubMed ID: 30578787
[TBL] [Abstract][Full Text] [Related]
40. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
